1. Anderson MC, Waldmeier PC, Tipton KF (1991) The inhibition of monoamine oxidase by brofaromine. Biochem Pharmacol 41: 1871?1877
2. Antonin KH, Jedrychowski M, Bieck PR (1990) Brofaromine. Pharmacodynamic and pharmacokinetic investigations in healthy subjects with a new reversible, selective MAO-A inhibitor. M�n Med Wochenschr 132 [Suppl 1]: 1, 13?17
3. Antonin KH, Kucher K, Fuchs L, Bieck PR, Schmidt E (1992) Investigation of dose proportionality and absolute bioavailability of brofaromine in healthy volunteers. Clin Neuropharmacol 15 [Suppl 1]: Pt B, 430B (Abstract)
4. Antonin KH, Fischer P, Nilsson E, Bieck PR (1994) Administration of L-DOPA and benserazide with the selective MAO-A inhibitor brofaromine in healthy volunteers: effect on blood pressure and DOPA metabolism. CINP, 120S
5. Antonin KH, Bieck PR (1994) Coadministration of brofaromine does not enhance insulin secretion and the hypoglycemic effect caused by glibenclamide. CINP, 120S